Page last updated: 2024-10-26

ebselen and Acoustic Trauma

ebselen has been researched along with Acoustic Trauma in 9 studies

ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.

Acoustic Trauma: Usually refer to hearing loss due to a single noise event such as an explosion or shotgun blast.

Research Excerpts

Excerpt	Relevance	Reference
"Ebselen treatment was well tolerated across all doses and no significant differences were seen in any haematological, serum chemistry, or radiological assessments between the ebselen groups and the placebo group."	2.84	Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. ( Antonelli, PJ; Griffiths, SK; Kil, J; Le Prell, CG; Lobarinas, E; Lynch, ED; Spankovich, C, 2017)
"Treatment with ebselen (4 mg/kg p."	1.34	Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. ( Gu, R; Kil, J; Lynch, ED; Pierce, C; Tran, H, 2007)

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (44.44)	29.6817
2010's	2 (22.22)	24.3611
2020's	3 (33.33)	2.80

Authors

Authors	Studies
Kil, J	5
Harruff, EE	1
Longenecker, RJ	1
Zhang, C	1
Li, Q	1
Chen, M	1
Lu, T	1
Min, S	1
Li, S	1
Mao, H	1
Chen, Y	1
Lobarinas, E	1
Spankovich, C	1
Griffiths, SK	1
Antonelli, PJ	1
Lynch, ED	4
Le Prell, CG	1
Rajguru, R	1
Pourbakht, A	1
Yamasoba, T	1
Gu, R	2
Pierce, C	2
Tran, H	1

Clinical Trials (6)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease[NCT02603081]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2015-12-31	Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005[NCT04677972]	Phase 3	254 participants (Actual)	Interventional	2022-08-02	Active, not recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease[NCT03325790]	Phase 2	149 participants (Actual)	Interventional	2017-09-28	Completed
Does the IMPase Inhibitor, Ebselen, Affect Emotional Processing and Brain Myo-inositol in Treatment-resistant Depression?[NCT05117710]	Phase 1	50 participants (Anticipated)	Interventional	2021-04-22	Recruiting
Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift[NCT01444846]	Phase 2	83 participants (Actual)	Interventional	2011-09-30	Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity[NCT02819856]	Phase 2	80 participants (Anticipated)	Interventional	2017-07-21	Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Treatment Emergent Adverse Events (TEAE)

"Number and severity of adverse events in patients treated with placebo versus SPI-1005.~Outcome Measure 1 includes all adverse events, including those which are not reported in the Adverse Event module, i.e., adverse events which did not result in death, were not Serious Adverse Events, and which were below the frequency threshold (5%) in any arm as required for reporting." (NCT03325790)
Timeframe: 8 weeks

Intervention	Participants (Count of Participants)
	Total Number of Patients with Treatment Emergent Adverse Events (TEAE)	Number of Patients with Mild TEAE	Number of Patients with Moderate TEAE	Number of Patients with Severe TEAE
200mg SPI-1005 Twice Daily (BID)	20	18	3	0
400mg SPI-1005 BID	20	18	7	2
Placebo	19	15	6	0

Trough Plasma Concentration of SPI-1005

Trough plasma concentration of SPI-1005 (ebselen) will be determined at certain time intervals (NCT03325790)
Timeframe: 2 weeks, 4 weeks, 8 weeks

Intervention	ng/mL (Mean)
	2 weeks	4 weeks	8 weeks
200mg SPI-1005 Twice Daily (BID)	27.2	19.7	0
400mg SPI-1005 BID	48.4	40.6	0

Efficacy of SPI-1005 on Hearing Loss

Improvement in sensorineural hearing loss from baseline using Pure Tone Audiometry (NCT03325790)
Timeframe: 8 weeks

Intervention	Participants (Count of Participants)
	Threshold Improvement from Baseline >=10 dB in at least 1 low frequency (250, 500, or 1000 Hz)72572366		Threshold Improvement from Baseline >=10 dB in at least 1 low frequency (250, 500, or 1000 Hz)72572367	Threshold Improvement from Baseline >=10 dB in at least 1 low frequency (250, 500, or 1000 Hz)72572368	Threshold Improvement >=10 dB in 2 adjacent low frequencies (250 and 500 Hz, or 500 and 1000 Hz)72572366	Threshold Improvement >=10 dB in 2 adjacent low frequencies (250 and 500 Hz, or 500 and 1000 Hz)72572367	Threshold Improvement >=10 dB in 2 adjacent low frequencies (250 and 500 Hz, or 500 and 1000 Hz)72572368
	No	Yes
Placebo	15
200mg SPI-1005 Twice Daily (BID)	16
400mg SPI-1005 BID	25
Placebo	26
200mg SPI-1005 Twice Daily (BID)	26
400mg SPI-1005 BID	16
Placebo	8
200mg SPI-1005 Twice Daily (BID)	7
400mg SPI-1005 BID	15
Placebo	33
200mg SPI-1005 Twice Daily (BID)	35

Efficacy of SPI-1005 on Word Recognition Score

Improvement in Words-in-Noise (WIN) test score from baseline. WIN test score, 0-35 words, in which a higher score means a better outcome. (NCT03325790)
Timeframe: 8 weeks

Intervention	Participants (Count of Participants)
	WIN Score Improvement from Baseline >=10%72572368		WIN Score Improvement from Baseline >=10%72572366	WIN Score Improvement from Baseline >=10%72572367	WIN Score Improvement from Baseline >=20%72572368	WIN Score Improvement from Baseline >=20%72572366	WIN Score Improvement from Baseline >=20%72572367	WIN Score Improvement from Baseline >= 4 words72572366	WIN Score Improvement from Baseline >= 4 words72572367	WIN Score Improvement from Baseline >= 4 words72572368
	Yes	No
Placebo	23
200mg SPI-1005 Twice Daily (BID)	23
400mg SPI-1005 BID	30
Placebo	18
200mg SPI-1005 Twice Daily (BID)	18
400mg SPI-1005 BID	10
Placebo	19
200mg SPI-1005 Twice Daily (BID)	17
400mg SPI-1005 BID	27
Placebo	22
200mg SPI-1005 Twice Daily (BID)	24
400mg SPI-1005 BID	13
Placebo	14
200mg SPI-1005 Twice Daily (BID)	13
400mg SPI-1005 BID	24
Placebo	27
200mg SPI-1005 Twice Daily (BID)	28
400mg SPI-1005 BID	16

Reviews

4 reviews available for ebselen and Acoustic Trauma

Article	Year
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. Hearing research, 2022, Volume: 413 Topics: Animals; Audiometry, Pure-Tone; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Humans; Is	2022
Noise-Induced Hearing Loss: Updates on Molecular Targets and Potential Interventions. Neural plasticity, 2021, Volume: 2021 Topics: Animals; Autophagy; Calcium; Clinical Trials, Phase II as Topic; DNA Repair; Drugs, Investigational;	2021
Military aircrew and noise-induced hearing loss: prevention and management. Aviation, space, and environmental medicine, 2013, Volume: 84, Issue:12 Topics: Acetylcarnitine; Acetylcysteine; Aerospace Medicine; Aircraft; Anti-Inflammatory Agents; Antioxidant	2013
Compounds for the prevention and treatment of noise-induced hearing loss. Drug discovery today, 2005, Oct-01, Volume: 10, Issue:19 Topics: Acetylcysteine; Allopurinol; Azoles; Glutathione Peroxidase; Hearing Loss, Noise-Induced; Humans; Is	2005

Trials

1 trial available for ebselen and Acoustic Trauma

Article	Year
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 2017, Sep-02, Volume: 390, Issue:10098 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Double-Blind Method; Female; Hea	2017

Other Studies

4 other studies available for ebselen and Acoustic Trauma

Article	Year
The role of oxidative stress in the susceptibility of noise-impaired cochleae to synaptic loss induced by intracochlear electrical stimulation. Neuropharmacology, 2021, 09-15, Volume: 196 Topics: Action Potentials; Aldehydes; Animals; Antioxidants; Cochlea; Cochlear Implants; Electric Stimulatio	2021
Ebselen attenuates cochlear damage caused by acoustic trauma. Hearing research, 2003, Volume: 181, Issue:1-2 Topics: Animals; Azoles; Cochlea; Cytoprotection; Differential Threshold; Dose-Response Relationship, Drug;	2003
Ebselen-mediated protection from single and repeated noise exposure in rat. The Laryngoscope, 2004, Volume: 114, Issue:2 Topics: Administration, Oral; Animals; Azoles; Cochlea; Evoked Potentials, Auditory, Brain Stem; Female; Hai	2004
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007
Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hearing research, 2007, Volume: 226, Issue:1-2 Topics: Animals; Antioxidants; Auditory Threshold; Azoles; Enzyme Induction; Female; Free Radical Scavengers	2007